NASDAQ: IVVDInvivyd Inc Stock
$0.47+0.05 (+11.9%)
Updated Jan 24, 2025
IVVD Price
$0.47
Fair Value Price
N/A
Market Cap
$56.58M
52 Week Low
$0.38
52 Week High
$5.20
P/E
-0.24x
P/B
0.68x
P/S
10.54x
PEG
N/A
Dividend Yield
N/A
Revenue
$11.56M
Earnings
-$225.14M
Gross Margin
92.3%
Operating Margin
-1,946.87%
Profit Margin
-1,946.9%
Debt to Equity
0.95
Operating Cash Flow
-$192M
Beta
1.41
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
IVVD Overview
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine IVVD's potential to beat the market
- IVVD doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
Value
N/A
Growth
N/A
Momentum
N/A
Sentiment
N/A
Safety
N/A
Financials
N/A
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
IVVD
RankedUnranked of 555
RankedUnranked of 555
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $22.17 | A | |
| $122.04 | A | |
| $2.96 | A |
Be the first to know about important IVVD news, forecast changes, insider trades & much more!
IVVD News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how IVVD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
IVVD is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
IVVD is good value based on its book value relative to its share price (0.68x), compared to the US Biotechnology industry average (5.04x)
P/B vs Industry Valuation
IVVD is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more IVVD due diligence checks available for Premium users.
Valuation
IVVD fair value
Fair Value of IVVD stock based on Discounted Cash Flow (DCF)
Price
$0.47
Fair Value
$1.81
Undervalued by
74.06%
IVVD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
IVVD price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.24x
Industry
-188.16x
Market
30.33x
IVVD price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.68x
Industry
5.04x
IVVD is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
IVVD's financial health
Profit margin
Revenue
$9.3M
Net Income
-$60.7M
Profit Margin
-653.1%
IVVD's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
IVVD's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$161.9M
Liabilities
$78.8M
Debt to equity
0.95
IVVD's short-term assets ($151.10M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
IVVD's short-term assets ($151.10M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
IVVD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$41.1M
Investing
-$5.0k
Financing
$61.0k
IVVD's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
IVVD vs Biotech Stocks
Invivyd Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.